Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 4Phase 1/2 2

Status

Unknown 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Gastrointestinal 3Lymphoid 1

Conditions

Multiple Myeloma 4

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Clarithromycin × Plasma cell × Clear all
NCT02516696 2023-06-05

BiRd vs Rd

Weill Medical College of Cornell University

Phase 3 Terminated
12 enrolled 19 charts
Plasma cell

Multiple Myeloma

NCT02575144 2022-02-01

GEM-CLARIDEX

PETHEMA Foundation

Phase 3 Unknown
286 enrolled
Plasma cell

Multiple Myeloma

NCT04287660 2021-10-25

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
20 enrolled
Plasma cell

Multiple Myeloma

NCT02248428 2017-09-06

CTd

Jinling Hospital, China

Phase 3 Unknown
130 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡